

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

EDITORIAL

Impact of Nosocomial Infections on Outcome: Myths and Evidence

JORDI RELLO, MD, PhD

392

ORIGINAL ARTICLES

Attributable Morbidity and Mortality of Catheter-Related Septicemia in Critically Ill Patients: A Matched, Risk-Adjusted, Cohort Study

LILIA SOUFIR, MD; JEAN-FRANÇOIS TIMSIT, MD; CÉDRIC MAHE, MD; JEAN CARLET, MD; BERNARD REGNIER, MD; SYLVIE CHEVRET, MD, PhD

396

Risk Assessment for Surgical-Site Infections in Orthopedic Patients

ANNETTE S. DE BOER, MSc; A. JOKE MINTJES-DE GROOT, PhD; ANTONIUS J. SEVERIJNEN, PhD; JAN MAARTEN J. VAN DEN BERG, MD; WILFRID VAN PELT, PhD

402

Nosocomial Methicillin-Resistant and Methicillin-Susceptible *Staphylococcus aureus* Primary Bacteremia: At What Costs?

MURRAY A. ABRAMSON, MD; DANIEL J. SEXTON, MD

408

A Survey of Methods Used to Detect Nosocomial Legionellosis Among Participants in the National Nosocomial Infections Surveillance System

ANTHONY E. FIORE, MD, MPH; JAY C. BUTLER, MD; T. GRACE EMORI, RN, MS; ROBERT P. GAYNES, MD

412

Vancomycin Use in a University Medical Center: Effect of a Vancomycin Continuation Form

MARTIN E. EVANS, MD; ERIC T. MILLHEIM, PHARM D; ROBERT P. RAPP, PHARM D

417

Nosocomial Tuberculosis Exposure in an Outpatient Setting: Evaluation of Patients Exposed to Healthcare Providers With Tuberculosis

NAOMI N. BOCK, MD; MARK J. SOTIR, MPH; PATRICIA L. PARROTT, RN, CIC; HENRY M. BLUMBERG, MD

421

CONCISE COMMUNICATIONS

Treatment of a *Legionella pneumophila*-Colonized Water Distribution System Using Copper-Silver Ionization and Continuous Chlorination

AMAYA BIURRUN, MD; LUIS CABALLERO, MD; CARMEN PELAZ, PhD; ELENA LEÓN, ICP; ALBERTO GAGO, MD

426

Effect of Zidovudine Postexposure Prophylaxis on the Development of HIV-Specific Cytotoxic T-Lymphocyte Responses in HIV-Exposed Healthcare Workers

RONNIE D'AMICO, DO; LIGIA A. PINTO, MD; PETER MEYER, PhD; ALAN L. LANDAY, PhD; ALAN A. HARRIS, MD; MARIO CLERICI, MD; JAY A. BERZOFSKY, MD, PhD; GENE M. SHEARER, PhD; HAROLD A. KESSLER, MD

428

Occupational Exposure and Voluntary Human Immunodeficiency Virus Testing: A Survey of Maryland Hospitals

LIZA SOLOMON, DRPH; CHARLOTTE THOMPSON, MS; LINDA SQUIERS, PhD; KAREN WULFF, BS; GEORGES BENJAMIN, MD

430

Continued inside.

Reducing the incidence of nosocomial UTI

Are you even on the map?

The BARDEX® I.C. Foley Catheter can put you there.

Each year, over 900,000 nosocomial urinary tract infections occur in hospitals throughout the U.S. – seriously impacting quality of care.

The silver and hydrogel-coated BARDEX I.C. Foley Catheter has been proven to reduce the incidence of NUTIs. The published examples noted below are just a few of the more than 600 success stories involving hospitals that significantly reduced infection rates and costs after converting to the BARDEX I.C. system.

For more information on the BARDEX I.C. Foley Catheter, contact your BARD Representative or call 1-800-526-4455. You can also visit our website at www.bardmedical.com.

Graduate Philadelphia, PA
11,210 annual admissions
50% reduction in NUTI
AUA-1998⁷

Kaiser Permanente Sunnyside
Clackmas, OR
12,178 annual admissions
69% reduction in NUTI
APIC-1998¹

Poudre Valley
Fort Collins, CO
13,264 annual admissions
53% reduction in NUTI
APIC-1998³

St. Michael Health Care Ctr.
Texarkana, TX
3,919 annual admissions
56% reduction in NUTI
APIC-1997⁴

U of W
Madison, WI
19,100 annual admissions
25% reduction in NUTI
ICAAC-1998⁵

UVA
Charlottesville, VA
27,116 annual admissions
48% reduction in NUTI
SHEA-1998⁶

N. Broward Hospital
Ft. Lauderdale, FL
23,327 annual admissions
58% reduction in NUTI
SHEA-1998⁶

Wilson Memorial Hospital
Wilson, NC
7,985 annual admissions
37% reduction in NUTI
APIC-1996⁸

BARD

Bard Medical Division
C.R. Bard, Inc.
8195 Industrial Boulevard
Covington, GA 30014
800-526-4455

References:

1. Data on file, BARD Medical Division, Covington, GA.

2. Hospital Epidemiology and Infection Control, 1996. Nosocomial Urinary Tract Infections, Section III, Chapter 10, p. 140.
3. American Journal of Infection Control, April 1998, Vol. 26 No.2.
4. American Journal of Infection Control, April 1997, Vol. 25 No.2.

5. Abstracts of 38th ICAAC, September 1998.
6. Infection Control and Hospital Epidemiology, April 1998.
7. Journal of Urology, May 1998.
8. American Journal of Infection Control, April 1996, Vol. 24 No.2.

BARDEX IC is a registered trademark of C.R.BARD, Inc. or an affiliate.

BARDEX® I.C.
SILVER/HYDROGEL FOLEY CATHETER



The Society for Healthcare Epidemiology of America

1999 SHEA/CDC

Training Course in Hospital Epidemiology

Program

The program will be held May 1-4, 1999 at the Wyndham Franklin Plaza Hotel, Philadelphia, Pennsylvania. Timothy W. Lane, M.D., Gina Pugliese, R.N., and Julie Gerberding, M.D. will chair the program.

Purpose

This program, developed by the Society for Healthcare Epidemiology of America (SHEA), and the Centers for Disease Control and Prevention (CDC), is intended for infectious disease fellows and new hospital epidemiologists. It emphasizes hands-on exercises in which participants work in small groups to detect, investigate, and control epidemiological problems encountered in the hospital setting. These work sessions are supplemented with lectures and seminars covering fundamental aspects of hospital epidemiology and surveillance, epidemic investigation, transmission and control of nosocomial infections, disinfection and sterilization, employee health, isolation systems, regulatory compliance, and quality improvement.

Who Should Attend

You should attend if you are a hospital epidemiologist or an infection control practitioner or if you are looking for a course that will provide you the most current information concerning infection control practices and epidemiological methods in health care. This fundamental program will provide you with the opportunities to find solutions to real situations that will occur in the hospital setting. Intensive problem solving sessions are supplemented with lectures and seminars presented by leading authorities.

Scholarships

Scholarships in the amount of \$1,000 will be awarded to infectious disease fellows for the program to defray the special course fee for fellows of \$350 and expenses incurred in attending the training program.

Interested fellows must submit a letter of no more than one page describing why they would like to have additional training in hospital epidemiology. A letter from the fellow's program director outlining the applicant's qualifications and suitability for the course also is required. The deadline for receipt of scholarship applications for the course is March 26, 1998.

The SHEA Educational Activities Committee will select the scholarship recipients based on review of these letters. Winners will be notified in September.

Nominations

Please send scholarship applications to:

Timothy W. Lane, M.D.
c/o The Society for Healthcare Epidemiology of America
19 Mantua Road
Mt. Royal, NJ 08061

Fees

Individual Registrants	\$495
Fellows in Infectious Disease	\$350

Credits

The Society for Healthcare Epidemiology of America (SHEA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

SHEA designates this continuing education activity for up to 23 hours in Category 1 of the Physician's Recognition Award of the American Medical Association.

The SHEA/CDC Training Course is AACN (American Association of Critical Care Nurses) approved for 28.5 hours.

General Course Information

Information regarding the schedule, hotel and travel accommodations, discount airfare, and course fees are available from SHEA (609) 423-7222 x350. Note that application for a scholarship does not constitute enrollment in the program. This must be done separately.

Scholarship Awards provided in part by an educational grant from Pfizer Pharmaceuticals.



Labs • NHO • Pratt • Roerig • Specialty
U.S. Pharmaceuticals Group

Getting splashed is
not always fun and
games.



Get
SplashGuard IITM
or get wet.



There was a time when getting splashed was all part of the game, but accidental contact with urine is never fun. So protect yourself with the SplashGuard II Drain Spout from Kendall. It's designed to open and close easily with one hand, and makes emptying the bag safer and neater. And with all of that protection, getting splashed will remain a thing of the past.

KENDALL

15 Hampshire Street, Mansfield, MA 02048 1-800-962-9888

A **tyco** INTERNATIONAL LTD. COMPANY

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY[®]

CONTENTS

Continued from cover

Monitoring Rotavirus Environmental Contamination in a Pediatric Unit Using Polymerase Chain Reaction HERVÉ SOULE, PHARM; OÏLE GENOULAZ, DRTECH; BÉNÉDICTE GRATACAP-CAVALLIER, MD; MARIE REINE MALLARET, MD; PATRICE MORAND, MD; PATRICE FRANÇOIS, MD; DOMINIQUE LUU DUC BIN, PHARM; AGNÈS CHARVIER, MD; CÉCILE BOST-BRU, MD; JEAN-MARIE SEIGNEURIN, MD, PhD	432
Evaluation of a Disinfection Procedure for Hysteroscopes Contaminated by Hepatitis C Virus CATHERINE SARTOR, MD; REMI NICOLAS CHARREL, MD; XAVIER DE LAMBALLERIE, MD; ROLAND SAMBUC, MD; PHILIPPE DE MICCO, MD; LEON BOUBLI, MD	434
Perioperative Antibiotic Prophylaxis in Spanish Hospitals: Results of a Questionnaire Survey CARLES CODINA, DPHARM; ANTONI TRILLA, MD, MSC; NURIA RIERA, DPHARM; MONTSERRAT TUSET, DPHARM; XAVIER CARNE, MD; JOSEP RIBAS, DPHARM; MIGUEL-ANGEL ASENJO, MD; THE HOSPITAL PHARMACY ANTIMICROBIAL PROPHYLAXIS STUDY GROUP	436
THE INTERNATIONAL PERSPECTIVE Implementation of a Practical Antibiotic Policy in the Czech Republic MILAN KOLAR, MD; TOMÁS LÁTAL, MSc	440
INFORMATION MANAGEMENT Implementation of an Interactive Computer-Assisted Infection Monitoring Program at the Bedside ALEXANDRA HEININGER, MD; ADOLF H. NIEMETZ; MARTIN KEIM; REINHOLD FRETSCNER, MD; GERD DÖRING, PhD; KLAUS UNERTL, MD	444
LETTERS TO THE EDITOR Temporally Overlapping Nosocomial Outbreaks of <i>Serratia marcescens</i> Infections: An Unexpected Result Revealed by Pulsed-Field Gel Electrophoresis HEIDRUN PELTROCHE-LLACSAHUANGA, MD; RUDOLF LÜTTICKEN, MD; GERHARD HAASE, MD	387
Another Disinfectant for Enterococci ALICE N. NEELY, PhD; MATTHEW P. MALEY, MS	388
Infection Control Practices of General Dental Practitioners JACK W. SHIELDS, MD, MS	389
MEDICAL NEWS GINA PUGLIESE, RN, MS; MARTIN S. FAVERO, PhD	449
SHEA NEWS ANDREAS VOSS, MD, PhD	452

To view abstracts of these articles,
visit us on the Internet at <http://www.slackinc.com/general/iche>

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

PUBLISHER: Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

SHEA: 19 Mantua Rd., Mt. Royal, NJ 08061; telephone, 609-423-0087; fax, 609-423-3420; e-mail address, sheahq@talley.com.

COPYRIGHT 1999 The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

SUBSCRIPTIONS: Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$105.00; Two years-\$143.00; Three years-\$178.00; Institutional: One year-\$128.00; Two years-\$178.00; Three years-\$228.00. Fellows: \$52.50 per year with proof of training status. Canada: \$20.00 additional each year plus 7% for Canadian Goods & Services tax; Overseas surface, \$145.00 each year; Overseas air mail, \$190.00. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$20.00 all other countries.

INSTRUCTIONS TO AUTHORS: Authors may submit manuscripts prepared in accordance with the 1997 revision of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals." The Uniform Requirements has been published in several journals, including *Infect Control Hosp Epidemiol* 1997;18:457-464 and *Ann Intern Med* 1997;126:36-47. A digital version is available on our web site (<http://www.slackinc.com/general/iche/ichehome.htm>). Submit to ICHE Editorial Offices, Vanderbilt University School of Medicine, A-1131 Medical Center North, Nashville, TN 37232-2637, USA. All submissions must be accompanied by copyright form(s) signed by all authors (see January issue or our web site).

REPRINTS: All requests to reprint or use material published herein should be addressed to Karen Lambertson, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Karen Lambertson at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

CHANGE OF ADDRESS: Notice should be sent to the publisher 6 weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Periodicals postage paid at Thorofare, New Jersey 08086-9447 and at additional mailing offices. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RNdex Top 100.

EDITORIAL OFFICES

Vanderbilt University School of Medicine
A-1131 Medical Center North
Nashville, TN 37232-2637
(615) 343-1095; (615) 343-1882 (FAX)
Email: iche@mcm.vanderbilt.edu

EDITOR

Michael D. Decker, MD, MPH

MANAGING EDITOR

Susan Cantrell

STATISTICAL EDITOR

Beverly G. Mellen, PhD

SENIOR ASSOCIATE EDITORS

C. Glen Mayhall, MD

Gina Pugliese, RN, MS

William Schaffner, MD

ASSOCIATE EDITORS

Donald A. Goldmann, MD

Didier Pittet, MD, MS

Andreas Widmer, MD, MS

SECTION EDITORS**Beyond Infection Control:****The New Hospital Epidemiology**

Bryan P. Simmons, MD

Stephen B. Kritchevsky, PhD

Memphis, Tennessee

Wing Hong Seto, MD

Hong Kong

Disinfection and Sterilization

William A. Rutala, PhD, MPH

Chapel Hill, North Carolina

Emerging Infectious Diseases

Larry J. Strausbaugh, MD

Portland, Oregon

Robert W. Pinner, MD

Atlanta, Georgia

From the Laboratory

Marcus Zervos, MD

Royal Oak, Michigan

Fred C. Tenover, PhD

Atlanta, Georgia

Information Management

John A. Sellick, DO

Buffalo, New York

The International Perspective

Mary D. Nettleman, MD, MS

Richmond, Virginia

Issues in Surgery

James T. Lee, MD, PhD

St. Paul, Minnesota

Medical News

Gina Pugliese, RN, MS

Chicago, Illinois

Martin S. Favero, PhD

Irvine, California

Practical Healthcare Epidemiology

Loreen A. Herwaldt, MD

Iowa City, Iowa

SHEA News

Andreas Voss, MD, PhD

Nijmegen, The Netherlands

Statistics for Hospital Epidemiology

David Birnbaum, PhD, MPH

Sidney, British Columbia, Canada

Topics in Long-Term Care

Philip W. Smith, MD

Omaha, Nebraska

Topics in Occupational Medicine

David Weber, MD, MPH

Chapel Hill, North Carolina

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY®

EDITORIAL ADVISORY BOARD

- | | |
|--------------------------------------|---|
| Jacques F. Acar, MD | Paris, France |
| J. Wesley Alexander, MD | Cincinnati, Ohio |
| Paul Arnow, MD | Chicago, Illinois |
| Graham A.J. Ayliffe, MD | Birmingham, United Kingdom |
| Neil L. Barg, MD | Yakima, Washington |
| Elizabeth Ann Bolyard, RN, MPH, CIC | Atlanta, Georgia |
| John M. Boyce, MD | Providence, Rhode Island |
| Professor Dr. Ilja Braveny | Munich, Federal Republic of Germany |
| Christian Brun-Buisson, MD | Creteil, France |
| Charles Bryan, MD | Columbia, South Carolina |
| Donald E. Craven, MD | Boston, Massachusetts |
| Sue Crow, MSN, RN, CIC | Shreveport, Louisiana |
| Franz Daschner, MD | Freiburg, Federal Republic of Germany |
| Leigh G. Donowitz, MD | Charlottesville, Virginia |
| Charles E. Edmiston, Jr., PhD | Milwaukee, Wisconsin |
| Theodore C. Eickhoff, MD | Denver, Colorado |
| Bruce Farber, MD | Manhasset, New York |
| Victoria J. Fraser, MD | St. Louis, Missouri |
| Peter C. Fuchs, MD, PhD | Black Butte, Oregon |
| Richard A. Garibaldi, MD | Farmington, Connecticut |
| Robert Gaynes, MD | Atlanta, Georgia |
| Veivl Greene, PhD, MPH | Beer Sheva, Israel |
| David W. Gregory, MD | Nashville, Tennessee |
| David K. Henderson, MD | Bethesda, Maryland |
| Peter N.R. Heseltine, MD | Los Angeles, California |
| Karen Hoffmann, RN, CIC, MS | Chapel Hill, North Carolina |
| Marguerite McMillan Jackson, RN, PhD | San Diego, California |
| Janine Jagger, MPH, PhD | Charlottesville, Virginia |
| William R. Jarvis, MD | Atlanta, Georgia |
| Douglas S. Kernodle, MD | Nashville, Tennessee |
| Robert H. Latham, MD | Nashville, Tennessee |
| Lewis B. Lefkowitz, MD | Nashville, Tennessee |
| Hsieh-Shong Leu, MD, MSc | Taipei, Taiwan |
| Jack Levy, MD | Brussels, Belgium |
| Victor Lorian, MD | Bronx, New York |
| Dennis G. Maki, MD | Madison, Wisconsin |
| William J. Martone, MD | Bethesda, Maryland |
| Allison McGeer, MD | Toronto, Ontario, Canada |
| John E. McGowan, Jr., MD | Atlanta, Georgia |
| Jonathan L. Meakins, MD, DSc | Montreal, Quebec, Canada |
| Raf Mertens, MD | Brussels, Belgium |
| Robert R. Muder, MD | Pittsburgh, Pennsylvania |
| Joseph M. Mylotte, MD, CIC | Buffalo, New York |
| Lindsay Nicolle, MD | Winnipeg, Manitoba, Canada |
| Juhani Ojajarvi, MD | Helsinki, Finland |
| Michael T. Osterholm, PhD, MPH | Minneapolis, Minnesota |
| Jan Evans Patterson, MD | San Antonio, Texas |
| Sindy M. Paul, MD | Trenton, New Jersey |
| Michael A. Pfaller, MD | Iowa City, Iowa |
| Samuel Ponce de Leon, MD, MSc | Mexico City, Mexico |
| Isaam Raad, MD | Houston, Texas |
| Manfred L. Rotter, MD, DipBact | Vienna, Austria |
| Theodore Sacks, MD | Jerusalem, Israel |
| William E. Scheckler, MD | Madison, Wisconsin |
| Kent Sepkowitz, MD | New York City, New York |
| Denis Spelman, MD | Prahran Victoria, Australia |
| Michael L. Tapper, MD | New York, New York |
| Clyde Thornberry, PhD | Brentwood, Tennessee |
| Professor Leonid P. Titov | Minsk, Republic of Belarus |
| Timothy R. Townsend, MD | Millwood, Virginia |
| Antoni Trilla, MD, PhD | Barcelona, Spain |
| Professor Wang Shu-Qun | Beijing, People's Republic of China |
| J. John Weems, Jr., MD | Greenville, South Carolina |
| Robert A. Weinstein, MD | Chicago, Illinois |
| Professor Dr. W. Weuffen | Greifswald, Federal Republic of Germany |
| Sergio B. Wey, MD | São Paulo, Brazil |
| Rebecca Wurtz, MD | Evanston, Illinois |

SLACK Incorporated

6900 Grove Road
Thorofare, New Jersey 08086
(609) 848-1000

Vice President/Group Publisher

Richard N. Roash

Publisher

John C. Carter

Editorial Director

Jennifer Kilpatrick

Production Editor

Shirley P. Strunk, ELS

Assistant Editor

Eileen C. Anderer

Circulation Manager

Lester J. Robeson, CCCP

Production Director

Christine Malin

Production Coordinator

Joanne Patterson

Publishing Director/ Advertising

Wayne McCourt

Pharmaceutical Group Sales Director

Michael LoPresti

Advertising Sales Representative

Jennine Kane


Classified/Recruitment Sales Manager

Kathy Huntley

Classified/Recruitment Sales Representative

Carla Maxie

Why the best thermometer is the one you throw away.



Right now, all sorts of nasty bugs are getting a "free ride" from bed to bed in hospitals, all across America. Electronic and tympanic thermometers may be among their favorite vehicles.

These shared instruments (with their probes, cords and boxes) are excellent carriers for everything from MRSA and VRE to *C. difficile*.

Fortunately, NexTemp™ can help.

There's no hardware to become colonized, and it's disposable. NexTemp puts the bugs where they belong. In the trash can.

Now we know what you're thinking, "is it accurate?" NexTemp "Precision Phase-Change" (PPC) thermometers meet stringent ASTM accuracy requirements. As for reliability, NexTemp Thermometers won't prefire irreversibly and never need resetting in the refrigerator.

In addition to incredible accuracy and reliability, NexTemp Thermometers

are quick-reading and simple to use. Plus they've got a 5-year shelf life without the need for any special temperature-controlled storage.

Of course the best way to test NexTemp is to try it yourself.

For your free sample just call us at 888.930.4599. Or see our web site at www.medicalindicators.com.

NexTemp Disposable Thermometers. Because the next step in infection control is throwing away the world's best thermometer!



The last black dot indicates a temperature of 98.8 F

NexTemp™
by **MEDICAL INDICATORS**

SHEA

CDC Guidelines
for Surveillance
Prevention & Control
of Nosocomial
Infections

**All In One
Single Volume
for only \$99.00***

Plus Shipping
& Handling

Urinary Tract Infections • Surgical Wound Infections
Handwashing and Environmental Control
Hospital Personnel • HIV and HBV Exposure-
Prone Procedures • Pneumonia Tuberculosis
Vancomycin Resistance • IV Device-Related
Infections • Isolation Precautions
HIV Post-Exposure Chemoprophylaxis
HCV Post-Exposure Prophylaxis
and Index of SHEA Position Papers

Foreword by Julia S. Garner, RN, MN

To Order Call 1-800-552-0076


International Orders 414-634-0806
E-mail ETNAComm@aol.com

* SHEA Journal Subscribers mention this ad for 10% discount.
Orders outside the U.S.A., Canada, & Mexico are \$175.00 each. SJ198

Consumer
Information
Catalog



www.pueblo.gsa.gov



9 out of 10 mice prefer the Consumer Information Catalog online. Just point and click your way to www.pueblo.gsa.gov and you'll find more than 250 free publications ready to read or download.

U.S. General Services Administration

Mothers. Spouses. (maybe) Medical Matrix.

What do they have in common? You place your trust in them. When searching the Internet for credible medical information, you need a resource you can trust. *The Lancet* quotes that "Medical Matrix is the most comprehensive compendium of reliable medical information on the Internet."

MEDICAL MATRIX L.L.C.

<http://www.medmatrix.org>

**The largest, peer-reviewed directory to the medical Internet.
Free registration.**



be safer


Just one needlestick injury could change your life.

NMT Safety Syringe prevents contact with potentially contaminated needles.

Its revolutionary automatic retraction mechanism locks the used needle within the syringe. Afterwards, NMT Safety Syringe can be disposed of easily and safely — no more exposed needles sticking out of sharps containers or anywhere else.

NMT Safety Syringe is brilliantly simple, effective and fast. No extra steps are needed to activate the safety feature and there are no manually manipulated covers for you to handle.

NMT Safety Syringe dramatically reduces the risk of needlestick, which is reassuring for you, your patients, your coworkers, and the public.



For more information, call
New Medical Technology, Inc.

1500 West Oak Street, Suite 200
Zionsville, IN 46077

Phone 317.733.9560

Toll Free 800.522.1512

Fax 317.733.9563

Email newmedical@aol.com

www.new-medical-technology.com

Don't risk needlestick
NMT
Safety Syringe

SHEA/ESGNI

Training Course in Hospital Epidemiology



October 29-November 2, 1999

Beach & Golf Resort Ooghduyne
Julianadorp aan Zee
The Netherlands

This intensive training program is designed for those who have responsibility for hospital epidemiology and infection control programs. It is sponsored by the Society for Healthcare Epidemiology of America and the European Study Group of Nosocomial Infections (ESGNI) of the European Society for Clinical Microbiology and Infectious Diseases (ESCMID). The course is taught by renowned experts from the United States and Europe who are dedicated to continuous quality improvement in infection control and the application of epidemiology within the hospital setting. Topics to be addressed include, but are not limited to, patterns of transmission of nosoco-

mial infections; risk factors for nosocomial infections; approach to epidemic investigation; molecular typing; disinfection and sterilization; epidemic in the OR; introduction to surveillance; use of computerized data in outbreak investigations; MRSA; isolation systems and TB; investigation of excess mortality in the NICU; employee safety and control of bloodborne pathogens; control of antibiotic resistance and antibiotic policies.

For more information, contact University Hospital Nijmegen, 440 MMB, c/o A. Voss, MD, PhD, PO Box 9101, 6500 HB Nijmegen, The Netherlands; fax: 31-24-354-0216; e-mail: y.beeuwkes@mmb.





THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA
Membership Application

Name: _____ Degree(s): _____

Hospital position (if applicable): _____

SPECIAL INTEREST GROUPS:

- Pediatric Surgical Other (Specify)

COMMITTEES:

- AIDS/TB Committee Annual Meeting Committee Education Committee Financial Advisory Committee International Assistance Committee Long Term Care Committee Membership Committee Nominating Committee Publications Committee

Business Address: _____

City State Zip Code

Business Telephone: () FAX: ()

E-Mail: _____

Home Address: _____

City State Zip Code

Home Telephone: ()

Indicate preferred address for correspondence, journal, and membership directory listing Home Business

How/Where did you hear about SHEA? _____

MEMBERSHIP FEE: (Non-U.S. members pay with draft for U.S. dollars)

Check one:

- Active Membership Doctoral Degree Invited Membership Associate Membership

Membership Fee includes subscription to Society's official journals, Infection Control and Hospital Epidemiology AND Clinical Performance and Quality Health Care.

*\$53.00 of dues will go for mailing of journals outside U.S. and Canada.


Method of Payment: Check Visa MasterCard American Express

Credit Card # Exp. Date Authorized Signature

Your credit card statement will read "Talley Management Group, Inc."

Send Application and Remittance TO: SHEA Membership Department 19 Mantua Road Mt. Royal, NJ 08061 609-423-0087 609-423-3420 fax sheahq@shea-smarthub.com

What if the box




It's all the rage these days to "think outside the box." But at Arrow, we find just the idea of a box an unnecessary limitation.

isn't really a box?

We believe revolutionary products require committed, inspired, visionary thinking. The kind of thinking that goes into developing ARROWgard[®], the first antimicrobial surface treatment for central venous catheters. By providing a barrier against catheter-related infections, it dramatically improves patient outcomes and quality of life. Changing the medical world forever.

What about all those ideas we're working on now?

At Arrow, you won't hear the mantra to think outside the box. Our kind of thinking has no boundaries.



Powered by
ARROW
innovation™

www.arrowintl.com

For more information,
call your Arrow representative
or contact us by calling
1-800-523-8446 or 610-378-0131.

Coming soon: ARROWgard Blue Plus™

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc Copyright and Republication Policy

The Society for Hospital Epidemiology of America (SHEA) and SLACK Inc hold copyright on *Infection Control and Hospital Epidemiology*. We request that all authors of works transfer to SHEA and SLACK Inc all rights, title, and interest to such works, including copyright. In accord with the Copyright Act of 1976, we must acquire every author's signature to effect the transfer. A written work cannot be considered for publication until the "Assignment of Copyright" form is signed by the author or authors and is on file at the editorial offices. Please submit this signed form with your manuscript. In the event that a manuscript is not accepted for publication, this agreement will be returned to the authors.

Signed "Assignment of Copyright" forms confirm that a work submitted has not previously been published, is not subject to copyright or other rights except those of the author to be transferred to SHEA and SLACK Inc, and is not under consideration for publication elsewhere, except under circumstances communicated in writing at the time the work is submitted.

Permission to reproduce any part of the works published by SHEA and SLACK Inc in *Infection Control and Hospital Epidemiology* in any form or by any means, electronic or mechanical, is not permitted without written permission from SLACK Inc.

Assignment of Copyright

In consideration of SLACK Incorporated and The Society for Hospital Epidemiology of America (collectively called the "Publisher") in publishing my (our) submitted manuscript, the undersigned hereby transfer(s), assign(s), and otherwise convey(s) all copyright in the manuscript to the Publisher. The copyright so conveyed includes any and all subsidiary forms of publication, such as electronic media. The undersigned declares that the manuscript is original and, to the best of the undersigned's knowledge, contains no matter that is libelous or unlawful or that infringes upon anyone else's rights of copyright.

In addition, we affirm that the work is the work of every author listed and is not under consideration for publication elsewhere, except under circumstances communicated to the Editor in writing at the time the work is submitted.

Manuscript Number (if known) _____

Authors _____

Title _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

Signature _____ Date _____

This form may be photocopied

Are You Doing All You Can to Stop Methicillin-Resistant *Staphylococcus aureus* Outbreaks Where They Originate...

The Nares

- *Bactroban* Nasal is indicated for eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers as part of a comprehensive infection control program to reduce the risk of infection among high-risk patients during MRSA outbreaks.¹

Single-use tube
(actual size)



- In a hospital study, *Bactroban* Nasal contributed to a dramatic reduction in MRSA infections and vancomycin costs during an outbreak.²
- Excellent safety profile¹

Please see brief summary of prescribing information on adjacent page.

References: 1. Bactroban® Nasal prescribing information, 1995. 2. Reagan DR, Dula RT, Palmer BH, et al. Control of MRSA in a VAMC with limited resources. Prog Abstr 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, U.S.A., Sept. 29-Oct. 2, 1991, p 104.

SB SmithKline Beecham
Pharmaceuticals

Bactroban®
Nasal mupirocin
calcium
2% ointment for intranasal use

BACTROBAN® NASAL (mupirocin calcium ointment), 2%
Brief summary. For complete prescribing information, see package insert.

INDICATIONS AND USAGE

Bactroban Nasal is indicated for eradication of nasal colonization with methicillin-resistant *Staphylococcus aureus* in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant *S. aureus* infection during institutional outbreaks of infections with this pathogen.

NOTE

- (1) There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with *S. aureus*.
- (2) There are insufficient data at this time to recommend use of *Bactroban* Nasal for general prophylaxis of any infection in any patient population.
- (3) Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in one domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks.

CONTRAINDICATIONS

Bactroban Nasal is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

WARNINGS

AVOID CONTACT WITH THE EYES. Application of *Bactroban* Nasal to the eye under testing conditions has caused severe symptoms such as burning and tearing. These symptoms resolved within days to weeks after discontinuation of the ointment.

In the event of a sensitization or severe local irritation from *Bactroban* Nasal, usage should be discontinued.

PRECAUTIONS

General: As with other antibacterial products, prolonged use may result in overgrowth of nonsusceptible microorganisms, including fungi. (See DOSAGE AND ADMINISTRATION in complete prescribing information.)

Information for Patients: Patients should: apply approximately one-half of the ointment from the single-use tube directly into one nostril and the other half into the other nostril; avoid contact of the medication with the eyes; discard the tube after using; press the sides of the nose together and gently massage after application to spread the ointment throughout the inside of the nostrils; and discontinue using *Bactroban* Nasal and call a health care practitioner if sensitization or severe local irritation occurs.

Drug Interactions: The effect of the concurrent application of intranasal mupirocin calcium and other intranasal products has not been studied. Do not apply mupirocin calcium ointment, 2% concurrently with any other intranasal products.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Long-term studies in animals to evaluate carcinogenic potential of mupirocin calcium have not been conducted. Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for mutagenicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice. Reproduction studies were performed in rats with mupirocin administered subcutaneously at doses up to 40 times the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium.

Pregnancy: Teratogenic Effects. Pregnancy Category B.

Reproduction studies have been performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 65 and 130 times, respectively, the human intranasal dose (approximately 20 mg mupirocin per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupirocin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, exercise caution when *Bactroban* Nasal is administered to a nursing woman.

Pediatric Use: Safety in children under the age of 12 years has not been established. (See CLINICAL PHARMACOLOGY in complete prescribing information.)

ADVERSE REACTIONS

Clinical Trials: In clinical trials, 210 domestic and 2,130 foreign adult subjects/patients received *Bactroban* Nasal ointment. Less than 1% of domestic or foreign subjects and patients in clinical trials were withdrawn due to adverse events. In domestic clinical trials, 17% (36/210) of adults treated with *Bactroban* Nasal ointment reported adverse events thought to be at least possibly drug-related. The incidence of adverse events thought to be at least possibly drug-related that were reported in at least 1% of adults enrolled in domestic clinical trials were as follows: headache, 9%; rhinitis, 6%; respiratory disorder, including upper respiratory tract congestion, 5%; pharyngitis, 4%; taste perversion, 3%; burning/stinging, 2%; cough, 2%; and pruritus, 1%.

The following events thought possibly drug-related were reported in less than 1% of adults enrolled in domestic clinical trials: blepharitis, diarrhea, dry mouth, ear pain, epistaxis, nausea and rash. All adequate and well-controlled clinical trials have been performed using *Bactroban* Nasal ointment, 2% in one arm and the vehicle ointment in the other arm of the study.

OVERDOSAGE

Following single or repeated intranasal applications of *Bactroban* Nasal to adults, no evidence for systemic absorption of mupirocin was obtained.

Manufactured by **DPT Laboratories, Inc.**, San Antonio, TX 78215

Distributed by **SmithKline Beecham Pharmaceuticals**, Philadelphia, PA 19101

BN:L1



The NIH Warren Grant
Magnuson Clinical Center

Unique Infection Control Opportunity

The National Institutes of Health's (NIH) Warren Grant Magnuson Clinical Center in Bethesda, MD is seeking an Infection Control Specialist. The Clinical Center is the Federal Government's 350-bed clinical research hospital at NIH. Infection Control in the Clinical Center's unique environment presents both interesting challenges and remarkable opportunities for career growth and development. Elements of this position include: surveillance, education and training, outbreak investigation, as well as the opportunity to conduct original or collaborative research in an institution that has as its mission the translation of basic science discoveries into clinical medicine. This position offers a remarkable opportunity to work in an exciting clinical research environment with internationally-renowned investigators who are shaping the 'medicine of the future'. Compensation is highly competitive. Please call Rogene Shank (301)-496-6924 to obtain the job vacancy announcement and an application; alternatively, see <http://www.ohrm.cc.nih.gov>. For additional information, please contact Dr. David Henderson (phone: 301-496-3515; email: dhenderson@nih.gov). Applications must be postmarked by July 30, 1999. NIH is an equal opportunity employer. U.S. citizenship required.

AMAZING OPPORTUNITIES

MOLECULAR EPIDEMIOLOGY TECHNOLOGISTS

The new Northwestern Memorial Hospital, opening in May 1999, will be a state-of-the-art medical center, equipped with the most modern diagnostic facilities. This is your opportunity to join a dynamic team of professionals who make "Amazing Things Happen."

MEDICAL TECHNOLOGIST MOLECULAR EPIDEMIOLOGY

Responsible for analyzing the genotypic similarity of microorganisms using molecular techniques including DNA extraction, enzyme restriction, gel electrophoresis, and photographic documentation of the DNA fingerprint band pattern. Provide data to our National Center of Excellence in Healthcare Epidemiology Hospital Infections Program sponsored by the NCID, CDC and HHS.

SENIOR TECHNOLOGIST MOLECULAR EPIDEMIOLOGY

In addition to performing molecular techniques, the senior technologist designs work-flow, maintains supply inventory strain, write schedules, procedures, consultations, abstracts, and articles.

MT (ASCP) preferred, with 2 years of relevant clinical laboratory experience and a background in molecular techniques. Please send resume to: RD, Northwestern Memorial Hospital, 310 E. Huron, Chicago, IL 60611. FAX: (312) 908-9288. E-mail: careers@nmh.org
An EEO/AA Employer

M Northwestern Memorial
Hospital
Amazing Things Happen™

© 1999 Northwestern Memorial Hospital